When does Bexsero’s patent protection expire?
Bexsero is a brand name for a multicomponent meningococcal group B vaccine. Patent “expiry” depends on which specific patent(s) you mean (for example, the vaccine composition, manufacturing process, or specific antigen/formulation IP), and on the country or region where marketing is authorized. With only the query “Bexsero and patent expiry,” no specific expiry date (or list of patents) can be stated reliably from the information provided.
How can you check Bexsero patent expiry in your country?
Patent timelines are jurisdiction-specific. To find the practical expiry date you care about (the point when competitors can potentially launch without infringing), you typically need to look up:
- The relevant patent family for the vaccine product in that country/region (e.g., EP, UK, US, CA, AU, JP).
- Whether the product benefits from any supplementary protection certificates (SPCs) or similar extensions.
- Whether there are additional “blocking” patents besides the core composition claims (often process and manufacturing know-how remain protected longer).
Does patent expiry automatically allow a cheaper “generic” Bexsero?
No. Vaccines like Bexsero are biologics, not standard small-molecule generics. Even after patents expire, competitors may still face:
- Regulatory and data exclusivity limits (separate from patents).
- Remaining patents covering manufacturing steps, formulation, or specific antigen components.
- Practical barriers to demonstrating comparable quality, consistency, and immunogenicity under the relevant regulatory pathway.
What else could delay market entry after a patent expires?
Even if some patents expire, other legal or regulatory factors can still slow entry:
- Product or process patents that continue to be in force.
- Litigation or settlements that temporarily prevent launch.
- Patent “evergreening” via additional filings in the same family (or related families).
- Exclusivity or reference product protections in the regulatory framework.
Are there risks of relying on an “expiry year” from secondary sources?
Yes. A single “expiry year” can be misleading because:
- Patents in the same product cluster may expire in different years.
- Country-level filings and any extensions (like SPCs) can shift the effective date.
- Some sources may refer to “first authorization” or exclusivity rather than patent expiry.
What would let me give a precise Bexsero expiry timeline?
If you share either:
- the country/region (e.g., UK, US, EU/EP, Canada), and
- whether you want the expiry of “composition” patents, “process” patents, or “effective launch/entry” date (including exclusivity),
I can then narrow down to the most relevant patent set and provide a timeline.
Sources
No sources were provided in the prompt, so I can’t cite any specific patent expiry information for Bexsero.